We protect your health through science
Investigation
Measles, rubella, mumps, parvovirus B19 and rabies
Research projects
Content with Investigacion .
Concesión del Proyecto de la Convocatoria 2019 de RETOS-COLABORACIÓN: Desarrollo de kits diagnósticos mediante PCR multiplex en tiempo real en formato líquido y gelificado para la detección de enfermedades víricas y sepsis. RTC2019-007023-1 / MPY 292/20. IP: Inmaculada Casas y Giovanni Fedele. 2020-2023. 442.653 €. Colaborador: Juan E. Echevarría
Publications
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group. EClinicalMedicine. 2022; 50:101529
PUBMED DOITranscriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection
Diez-Fuertes F, López-Huertas MR, García-Pérez J, Calonge E, Bermejo M, Mateos E, Martí P, Muelas N, Vílchez JJ, Coiras M, Alcamí J, Rodríguez-Mora S. Front Cell Dev Biol. 2022; 10:839813
PUBMED DOIImmunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group. Lancet. 2021; 398(10295):121-130
PUBMED DOIFirst Insight into the Genome Sequences of Two Linezolid-Resistant Nocardia farcinica Strains Isolated from Patients with Cystic Fibrosis
2: Valdezate S, Monzón S, Garrido N, Zaballos A, Medina-Pascual MJ, Azcona-Gutiérrez JM, Vilar B, Cuesta I. First Insight into the Genome Sequences of Two Linezolid-Resistant Nocardia farcinica Strains Isolated from Patients with Cystic Fibrosis. Genome Announc. 2017 Nov 16;5(46).
PUBMED DOIApoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens.
3: Martínez I, Oliveros JC, Cuesta I, de la Barrera J, Ausina V, Casals C, de Lorenzo A, García E, García-Fojeda B, Garmendia J, González-Nicolau M, Lacoma A, Menéndez M, Moranta D, Nieto A, Ortín J, Pérez-González A, Prat C, Ramos-Sevillano E, Regueiro V, Rodriguez-Frandsen A, Solís D, Yuste J, Bengoechea JA, Melero JA. Apoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens. Front Microbiol. 2017 Mar 1;8:276
PUBMED DOIAdditional Information
This group, together with the CNM Serology Laboratory (LS), houses the National Reference Laboratories for Rabies (RD 1940/2004) and Measles and Rubella (National Elimination Plan) that are integrated into the corresponding European networks. It has 10 self-developed techniques in its service portfolio (2 accredited by ENAC and 3 by the WHO). In addition, it attends to three CNM microbiological surveillance programs (measles and rubella, mumps and rabies). It is integrated into a CIBERESP group of which Juan E. Echevarría is head and in which other CNM researchers participate.
Research on MMR vaccine diseases is currently financed through an AESI project (PI15CIII/00023) of which Aurora Fernández García is co-PI and in which the LS, the CNE, the CAM (LRSP and the Epidemiology Service) and a network of primary care pediatricians participate. of the CAM.
Research on lisaviruses and other viruses associated with bats is currently funded through the VIROBAT-4 project (MINECO, SAF 2017-89355-P) of which Juan E. Echevarría is PI and in which the CNM Respiratory Viruses Laboratory, the Doñana Biological Station (CSIC) and the University of Alcalá de Henares participate.
This group, together with the CNM Serology Laboratory (LS), houses the National Reference Laboratories for Rabies (RD 1940/2004) and Measles and Rubella (National Elimination Plan) that are integrated into the corresponding European networks. It has 10 self-developed techniques in its service portfolio (2 accredited by ENAC and 3 by the WHO). In addition, it attends to three CNM microbiological surveillance programs (measles and rubella, mumps and rabies). It is integrated into a CIBERESP group of which Juan E. Echevarría is head and in which other CNM researchers participate.
Research on MMR vaccine diseases is currently financed through an AESI project (PI15CIII/00023) of which Aurora Fernández García is co-PI and in which the LS, the CNE, the CAM (LRSP and the Epidemiology Service) and a network of primary care pediatricians participate. of the CAM.
Research on lisaviruses and other viruses associated with bats is currently funded through the VIROBAT-4 project (MINECO, SAF 2017-89355-P) of which Juan E. Echevarría is PI and in which the CNM Respiratory Viruses Laboratory, the Doñana Biological Station (CSIC) and the University of Alcalá de Henares participate.